Glaucoma

Kang, Jessica; Tanna, Angelo P.

doi:10.1016/j.mcna.2021.01.004

Cited by 216 publications

(191 citation statements)

References 55 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…This is considered to be a cause of axonal transport disruptions in glaucoma [ 36 , 37 , 38 ]. In fact, elevated IOP is a well-known risk factor for the development of glaucoma, and most animal models of glaucoma mimic disease progression by inducing IOP rise [ 1 , 12 , 39 ]. It should be noted, however, that glaucoma can also develop in normotensive eyes and not every individual with ocular hypertension will develop glaucoma [ 1 , 40 ].…”

Section: Axonal Damage In Glaucomamentioning

confidence: 99%

“…Glaucoma is the only optic neuropathy known to cause a distinctive ONH “excavated” appearance [ 8 , 11 ]. The pathogenic processes that cause axonal degeneration in glaucoma have been in focus, aiming at a better understanding of the progression of glaucoma and how RGCs degenerate [ 1 , 12 ]. Among structural alterations of RGC axons, the impairment of axonal transport is acknowledged as a factor associated with axonal dysfunction and neurodegeneration in glaucoma [ 1 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Axonal Transport in Glaucoma

Dias

Luo

Ribas

et al. 2022

IJMS

View full text Add to dashboard Cite

Glaucoma is a neurodegenerative disease that affects the retinal ganglion cells (RGCs) and leads to progressive vision loss. The first pathological signs can be seen at the optic nerve head (ONH), the structure where RGC axons leave the retina to compose the optic nerve. Besides damage of the axonal cytoskeleton, axonal transport deficits at the ONH have been described as an important feature of glaucoma. Axonal transport is essential for proper neuronal function, including transport of organelles, synaptic components, vesicles, and neurotrophic factors. Impairment of axonal transport has been related to several neurodegenerative conditions. Studies on axonal transport in glaucoma include analysis in different animal models and in humans, and indicate that its failure happens mainly in the ONH and early in disease progression, preceding axonal and somal degeneration. Thus, a better understanding of the role of axonal transport in glaucoma is not only pivotal to decipher disease mechanisms but could also enable early therapies that might prevent irreversible neuronal damage at an early time point. In this review we present the current evidence of axonal transport impairment in glaucomatous neurodegeneration and summarize the methods employed to evaluate transport in this disease.

show abstract

Section: Axonal Damage In Glaucomamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Role of Axonal Transport in Glaucoma

Dias

Luo

Ribas

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…It is often difficult to distinguish between compressive optic neuropathy (CON) and glaucomatous optic neuropathy (GON) in chronic, painless visual loss with varying degrees of optic atrophy 1 – 3 . The more common primary optic neuropathy, GON, causes progressive optic atrophy and a corresponding visual field (VF) defect 4 . GON pathogenesis is primarily caused by translaminar pressure gradient insults to vulnerable optic nerve axons at the lamina cribrosa 5 , 6 .…”

Section: Introductionmentioning

confidence: 99%

Structural and functional differentiation between compressive and glaucomatous optic neuropathy

Laowanapiban¹,

Sathianvichitr

Chirapapaisan

2022

Sci Rep

View full text Add to dashboard Cite

Clinical diagnoses of slow, progressive, painless visual losses with various degrees of visual field (VF) losses and disc atrophy are often confused between suprasellar compressive optic neuropathy (CON) and open-angle glaucomatous optic neuropathy (GON). We plotted the thickness of the peripapillary retinal nerve fiber layer (RNFL) and macular ganglion cell-inner plexiform layer (GCIPL) against the mean deviation (MD) of the VF of 34 eyes of CON at diagnosis, 30 eyes of CON after therapy, 29 eyes of GON, and 60 eyes of healthy controls in a cross-sectional investigation. At diagnosis, a disproportionally early pattern of structural thinning compared with the corresponding VF losses was unique to CON. GON- and CON-specific thinning parameters were generally useful in differentiating GON and CON from moderate to severe MD losses, but early MD losses (0 to − 6 dB) overlapped with GON in a CON-stage specific manner. GON-specific thinning parameters, RNFL in the inferior sector, and inferior to temporal macular GCIPL ratio showed overlap with posttreatment CON in the early MD losses with AUCs of 0.916 (95% CI 0.860–0.971; P < 0.001) and 0.890 (95% CI 0.811–0.968; P < 0.001), respectively. In comparison, CON-specific thinning parameters, superonasal, and inferonasal GCIPL showed overlap with CON at diagnosis for early MD losses. Overall, the nasal-to-temporal macular GCIPL ratio showed good discrimination between CON and GON throughout the MD range, with an AUC of 0.923 (95% CI 0.870–0.976; P < 0.001). Comparing GON with all stages of CON, the cut-point of 0.95 showed the lower nasal-to-temporal GCIPL ratio had a sensitivity of 72% and specificity of 90% for CON. However, the cut-point of 1.10 showed the superior-to-inferior GCIPL ratio had a sensitivity of 60% and specificity of 98% for GON.

show abstract

“…Glaucoma is the second most prevalent cause of permanent blindness in the United States (US), and it is projected that 111.8 million people worldwide will have glaucoma by the year 2040 [ 1 , 2 ]. It is also a leading cause of blindness among African Americans and Hispanics [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma

Haga¹,

Waller²,

Ahuja³

et al. 2022

Cureus

View full text Add to dashboard Cite

Glaucoma is a common eye disorder and an irreversible cause of blindness worldwide. There are several treatment options for this condition, with the traditional first-line treatment being ophthalmologic drops. Although administered topically, it is associated with inadvertent systemic absorption leading to a potential for both local and systemic side effects. We discuss the case of a 71-year-old male who presented with a complaint of recurring episodes of distressing sensations including lightheadedness, dyspnea, chest pressure, and faintness. His past medical history included congestive heart failure, hypertension, hyperlipidemia, Barrett's esophagus, and glaucoma. Upon a thorough review of the patient's medications, it was discovered that he had recently been started on timolol ophthalmic drops. The patient then noted that his symptoms had begun after he started using the eye drops. After we recommended that the patient hold the use of the eye drops, these episodes stopped. When prescribing topical ophthalmologic drops, providers must educate patients on common systemic side effects of such drugs.

show abstract

Glaucoma

Cited by 216 publications

References 55 publications

The Role of Axonal Transport in Glaucoma

The Role of Axonal Transport in Glaucoma

Structural and functional differentiation between compressive and glaucomatous optic neuropathy

There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma

Contact Info

Product

Resources

About